

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Ehrin Armstrong

Page 1/9

Monday, January 25, 2021

MAIN ARENA 1

- 10:10 – 11:20** **Late breaking trial session: pioneering approaches and new data for BTK interventions**
MODERATOR:
Marianne Brodmann
Michael Lichtenberg
PANEL:
Francesco Liistro
Wei Guo
- 10:10 – 10:15 IN.PACT BTK randomized study: 9 month primary outcomes
Francesco Liistro
- 10:15 – 10:20 Chinese experience of DCB in BTK: 12 month results of the AcoArt II study
Wei Guo
- 10:20 – 10:25 Latest data of DCB in BTK: 12 month results of the AcoArt BTK Italy study
Francesco Liistro
- 10:25 – 10:30 Luminor in BTK: MERLION trial 12 month outcomes presented for the first time
Tjun Tang
- 10:30 – 10:35 Tensirolimus adventitial delivery to improve ANGIographic Outcomes below the knee (TANGO)
Ehrin Armstrong
- 10:35 – 10:40 PRESTIGE-study: 12 month results with the SELUTION sirolimus coated balloon in TASC C and D tibial occlusive disease
Tze Tec Chong
- 10:40 – 10:45 A pilot study examining the performance and safety of the temporary spur stent system in infrapopliteal arteries: first-time use with a Limus-coated balloon (DEEPER LIMUS)
Marianne Brodmann
- 10:45 – 10:50 DEEPER OUS trial: a multicenter, single arm trial of the novel temporary spur stent system used in conjunction with a commercially available, paclitaxel-coated balloon
Michael Lichtenberg
- 10:50 – 10:55 12 month data from the LimFlow PROMISE I US early feasibility study
Peter Schneider

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Ehrin Armstrong

Page 2/9

Monday, January 25, 2021

10:55 – 11:20 Live case transmission from Leipzig
 Universitätsklinikum Leipzig, Abt. Angiologie - Live case center

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Ehrin Armstrong

Page 3/9

Monday, January 25, 2021

MAIN ARENA 1

- 14:20 – 15:05** **LATE BREAKING TRIAL SESSION: New data and innovative concepts for treatment of femoral arteries – part II**
MODERATOR:
Thomas Zeller
Sabine Steiner
PANEL:
Brian DeRubertis
Ehrin Armstrong
Koen Deloose

FOCUS ON NEW DATA FOR COMPLEX LESIONS
- 14:20 – 14:25 IN.PACT global 4 year DCB alone vs. DCB + provisional stenting outcomes
Gunnar Tepe
- 14:25 – 14:30 24 month outcomes of the combination of Luminor and iVolution in 24 cm lesions: TINTIN trial
Koen Deloose
- 14:30 – 14:35 12 month outcomes from the Japanese post-market surveillance study of the Viabahn endoprosthesis as treatment for symptomatic peripheral arterial disease in the superficial femoral arteries
Osamu Iida
- 14:35 – 14:40 Outcomes in CLI patients treated with DCB: 4 year results from the IN.PACT global study
Michel Reijnen
- 14:40 – 14:45 REALITY study 12 month outcomes: safety and effectiveness of directional atherectomy followed by DCB
Brian DeRubertis
- 14:45 – 14:50 Laser atherectomy combined with drug-coated balloon angioplasty is associated with improved 1 year outcomes for the treatment of Tosaka II and III femoropopliteal in-stent restenosis
Ehrin Armstrong
- 14:50 – 14:55 In-tack restenosis vs. in-stent restenosis
Raghu Kolluri

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

LINC



Ehrin Armstrong

Page 4/9

Monday, January 25, 2021

- | | |
|---------------|--|
| 14:55 – 15:00 | TORUS2 late breaking clinical trial data: preliminary 12 month results from interim analysis of the TORUS stent graft
Michael Lichtenberg |
| 15:00 – 15:05 | Fully percutaneous femoropopliteal bypass of complex PAD: population analysis and 24 month results from the DETOUR ₁ clinical trial
Michael Piorkowski |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Ehrin Armstrong

Page 5/9

Wednesday, January 27, 2021

MAIN ARENA 1

- 12:30 – 13:15** **LUNCH SYMPOSIUM: Sustained limus release will make a difference to your patients**
supported by Medalliance
MODERATOR:
Michael Lichtenberg
Ehrin Armstrong
PANEL:
Tjun Tang
Marianne Brodmann
- 12:30 – 12:35 Introduction
Ehrin Armstrong
- 12:35 – 12:43 STEP Up with SELUTION SLR
Marianne Brodmann
- 12:43 – 12:48 Panel discussion
- 12:48 – 12:56 Importance of "No" Slow Flow Phenomena
Tjun Tang
- 12:56 – 13:01 Panel discussion
- 13:01 – 13:09 Why to choose Sirolimus for my CLI patients?
Michael Lichtenberg
- 13:09 – 13:15 Panel discussion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Ehrin Armstrong

Page 6/9

Wednesday, January 27, 2021

MAIN ARENA 1

16:45 – 18:45

CONNECT VIVA/LINC – Calcification: the last frontier in vascular therapy

MODERATOR:

Sean Lyden

Maureen Kohi

PANEL:

Raghu Kolluri

Ehrin Armstrong

16:45 – 16:50

Why does it form, what is the pathophysiology and is there a medical treatment on the horizon?

Raghu Kolluri

16:50 – 16:55

Calcium grading systems, which one is most accurate?

TBD

16:55 – 17:00

What are the best tools to prepare the calcified artery? Atherectomy, serration angioplasty, scoring, lithotripsy

Ehrin Armstrong

17:00 – 17:10

Panel discussion

17:10 – 17:40

Live case transmission from Leipzig

Universitätsklinikum Leipzig, Abt. Angiologie - Live case center

ADVICE ABOUT MANAGING CALCIFICATION IN DIFFERENT VASCULAR BEDS: VESSEL PREP, SCAFFOLDS, DRUG DELIVERY, AND OTHER ISSUES OF PROVIDING DEFINITIVE THERAPY IN THIS CHALLENGING SITUATION

17:40 – 17:45

Carotid

Kenneth Rosenfield

17:45 – 17:50

Aortoiliac

Safer Sabri

17:50 – 17:55

SFA-pop

Niten Singh

17:55 – 18:00

Tibial and BTA

Venita Chandra

18:00 – 18:15

Panel discussion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Ehrin Armstrong

Page 7/9

Wednesday, January 27, 2021

18:15 – 18:45

Live case transmission from Kingsport

Wellmont CVA Heart & Vascular Institute Kingsport - Live case center

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Ehrin Armstrong

Page 8/9

Friday, January 29, 2021

MAIN ARENA 1

- 07:00 – 09:00** **Novel techniques for treatment of complex BTK disease in CLI**
MODERATOR:
Jos van den Berg
Steven Kum
PANEL:
Roberto Ferraresi
Andrew Holden
Luis Palena
- 07:00 – 07:30 Live case transmission from Beijing
301 General Hospital of PLA, Beijing - Live case center
- 07:30 – 07:35 Tips and tricks for optimal angiographic imaging of BTK and foot arteries
Marco Manzi
- 07:35 – 07:40 Indirect vs. direct revascularization for CLI treatment: best practice in 2021
Roberto Ferraresi
- 07:40 – 07:45 Balloon angioplasty of infrapopliteal arteries: a proposed algorithm for optimal endovascular treatment
Ehrin Armstrong
- 07:45 – 07:50 Is bigger better in BTK arteries? The role luminal gain and how to achieve it?
Steven Kum
- 07:50 – 07:55 The PRELUDE-BTK study: novel serration angioplasty balloon for below-the-knee arteries
Andrew Holden
- 07:55 – 08:25 Live case transmission from Abano Terme
Policlinico Abano Terme - Live case center
- 08:25 – 08:30 Dissection repair in below-the-knee: evidence review and learnings from the TOBA II BTK trial
Michael Lichtenberg
- 08:30 – 08:35 Where do we stand with DCB therapy in BTK arteries?
Francesco Liistro
- 08:35 – 08:40 The drug-coated temporary spur stent system: innovation in drug delivery for treating CLI
Jihad Mustapha

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Ehrin Armstrong

Page 9/9

Friday, January 29, 2021

- | | |
|---------------|--|
| 08:40 – 08:45 | XTOSI 12 month results: Xtreme Touch-Neo (MagicTouch PTA) Sirolimus coated balloon for peripheral arterial disease
Edward Choke |
| 08:45 – 08:50 | BTK interventions in 2025: what is going to help to make BTK procedures more effective?
William Gray |
| 08:50 – 09:00 | Discussion and conclusion |

We are asking all faculty members to strictly respect the given time limits.